Shots:

• Pfizer’s two anticancer biosimilar Trazimera and Ruxience will be launched in Jan 2020- while the other in Feb 2020 respectively
• Ruxience (biosimilar- rituximab) was approved in July 2019 targeted for the treatment of non-Hodgkin lymphoma- chronic lymphocytic leukemia- and granulomatosis with polyangiitis and microscopic polyangiitis while Trazimera (biosimilar- trastuzumab) received approval in Mar’2019 for HER2-positive breast cancer and metastatic gastric cancer  
• Ruxience (rituximab-pvvr) is a mAb designed to target CD20 protein and is Pfizer’s third oncology biosimilar approved by the US FDA in 2019 with EMA’s awaited approval. Trazimera (trastuzumab-qyyp) is a mAb designed to target HER2 protein and has been evaluated in 500 patients in 20+ countries to date

Click here to­ read full press release/ article | Ref: Center for Biosimilars | Image: Twitter